GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Total Liabilities

PainReform (PainReform) Total Liabilities : $3.52 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PainReform Total Liabilities?

PainReform's Total Liabilities for the quarter that ended in Mar. 2024 was $3.52 Mil.

PainReform's quarterly Total Liabilities increased from Sep. 2023 ($2.25 Mil) to Dec. 2023 ($2.69 Mil) and increased from Dec. 2023 ($2.69 Mil) to Mar. 2024 ($3.52 Mil).

PainReform's annual Total Liabilities increased from Dec. 2021 ($0.99 Mil) to Dec. 2022 ($1.31 Mil) and increased from Dec. 2022 ($1.31 Mil) to Dec. 2023 ($2.69 Mil).


PainReform Total Liabilities Historical Data

The historical data trend for PainReform's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Total Liabilities Chart

PainReform Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 6.79 1.18 0.99 1.31 2.69

PainReform Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 1.34 2.25 2.69 3.52

PainReform Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PainReform's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.41+(0.03+-3.3306690738755E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.251+0)
=2.69

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=9.93-7.239
=2.69

PainReform's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.253+(0.015+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.253+0)
=3.52

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=5.369-1.848
=3.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PainReform Total Liabilities Related Terms

Thank you for viewing the detailed overview of PainReform's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


PainReform (PainReform) Business Description

Traded in Other Exchanges
N/A
Address
65 Yigal Alon Street, Tel Aviv, ISR, 6744316
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.